Nowadays, an emerging number of advanced therapies conquer the global market and, around the world, improve patients’ quality of life. Nanotechnology-related drug products are at the forefront of this development showing significant market potential and groundbreaking opportunities in cancer therapy.
Still the translation of nanomedicines from bench to bedside poses a major challenge to the scientific community. Key challenges arise from the bioanalytical methods required to characterize nanomedicines in preclinical and clinical studies. The talk provided a snapshot of our research activities in the characterization of nanomedicines in vitro and in silico. In this context, model-informed drug development has been effective in establishing a direct relationship between the physicochemical and in vitro properties of injectable nanocarriers and the in vivo performance seen during the phase I pharmacokinetic studies. Major hurdles in the development of novel drug delivery systems and their translation into the hospital were discussed from the perspective of a pharmaceutical scientist.